ChromoCure, Inc. (PINKSHEETS: KKUR) heralds the March 15, 2010 publication of “Polyploidization and Cancer.” This publication is viewed as a major turning point and paradigm shift in the diagnosis, therapy and cure of cancer. The Company views this as significant support of its long held theory of cancer and its Chromosomal Scanner detection technology. Published as part of Advances in Experimental Medicine and Biology Series: Vol. 676 (ISBN: 978-1-4419-6198-3) and edited by Randy Y.C. Poon, this book brings together leaders of the field to overview subjects relating to Polyploidization, aneuploidy and cancer.
This authoritative collection of research further corroborates recent studies by Mayo Clinic and others that have conclusively and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure designs its technology around the chromosomal theory of cancer.
The Company’s proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to other detection approaches presently employed by pathologists, including biomarker detection, in every measurable way. ChromoCure’s systems measure aneuploidy as the sole means of detecting cancer presence and measuring cancer progression. The system has a 100% effective accuracy rate, as verified in the recently published collaborative clinical testing with a major cancer clinic.
The company’s technology and related research opens the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. Given the significant change in scientific views currently underway, the company has aligned itself to focus its leadership status to therapeutics research. These new initiatives add to the Company’s existing scanner technologies which include proprietary designs, processes, and algorithms centered on chromosomal imbalance. The Company believes its technologies provide the foundation for significant advantages in delivering important results in diagnosis, therapy and cure.
The Company invites industry and scientific collaboration through its “Project Boveri: Find the Cure” initiative.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company’s proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company’s filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
